Inozyme Pharma (INZY) Competitors

Mineralys Therapeutics (NASDAQ:MLYS) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.

Do insiders & institutionals have more ownership in MLYS or INZY?

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by insiders. Comparatively, 12.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility and risk, MLYS or INZY?

Mineralys Therapeutics has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Which has better valuation and earnings, MLYS or INZY?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$177.81M	-$3.73	-4.29
Inozyme Pharma	N/A	N/A	-$71.17M	-$1.69	-2.34

Is MLYS or INZY more profitable?

Mineralys Therapeutics' return on equity of -67.97% beat Inozyme Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-67.97%	-62.40%
Inozyme Pharma	N/A	-88.42%	-57.02%

Does the MarketBeat Community prefer MLYS or INZY?

Inozyme Pharma received 43 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 95.24% of users gave Mineralys Therapeutics an outperform vote while only 82.89% of users gave Inozyme Pharma an outperform vote.

Company	Underperform	Outperform
Mineralys Therapeutics	Outperform Votes 20 95.24%	Underperform Votes 1 4.76%
Inozyme Pharma	Outperform Votes 63 82.89%	Underperform Votes 13 17.11%

Does the media favor MLYS or INZY?

In the previous week, Inozyme Pharma had 17 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 34 mentions for Inozyme Pharma and 17 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.83 beat Inozyme Pharma's score of -0.04 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inozyme Pharma	4 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts recommend MLYS or INZY?

Mineralys Therapeutics presently has a consensus price target of $38.00, suggesting a potential upside of 137.44%. Inozyme Pharma has a consensus price target of $11.75, suggesting a potential upside of 197.09%. Given Inozyme Pharma's higher probable upside, analysts plainly believe Inozyme Pharma is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inozyme Pharma	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Inozyme Pharma beats Mineralys Therapeutics on 10 of the 15 factors compared between the two stocks.